GenoCure.AI Ltd, the latest spin-off from Hadasit, is set to transform AI-driven precision oncology.
Co-founded by Prof. Shai Rosenberg, Head of the Unit for AI in Oncology and Head of the Hadassah Laboratory of Computational Biology of Cancer, along with Eitan Rubinow and Dr. Eitan Eliram, the company harnesses cutting-edge ML models like MESiCA and STAMP to translate DNA and RNA tumor sequencing data into actionable clinical recommendations and pharmacological clinical trials optimization.
GenoCure.AI’s AI engine is aimed to empower oncology professionals with clinico-Genomic insights, including mutational signatures, immunotherapy response predictions, and drug resistance profiles. For pharmaceutical companies, it offers advanced tools to accelerate oncology therapeutic development.

Hepacure Pharma is developing a novel peptide therapy targeting fatty liver diseases, particularly non-alcoholic fatty liver disease (NAFLD). The HepaCure Pharma is a spinout company developed from the groundbreaking research of Prof. Rifaat Safadi and his team member Dr. Johnny Amer at the Hadassah Medical Center Liver Institute.

NAFLD encompasses conditions marked by excess fat in the liver, increasing the risk of serious health issues like diabetes and kidney disease. Advanced NAFLD forms, such as non-alcoholic steatohepatitis (NASH), lead to inflammation, fibrosis, and, in some cases, incurable carcinoma.
Hepacure’s therapy centers on a peptide called Luji, which targets fibrosis and reactivates immune responses in the liver. This peptide blocks key proteins in the fibrosis pathway and reactivates natural killer (NK) cells, enabling them to target hepatic stellate cells (HSCs), which contribute to fibrosis. Research highlights Neuroligin-4 (NLGN4X) as a factor in NK cell inhibition, leading to fibrosis progression. Luji modulates the NLGN4-Nrx1β protein interaction, aiming to prevent fibrosis advancement.

Hopec pharma is dedicated to develop a groundbreaking  next generation immunotherapy treatment for bladder cancer. The technology invented by Dr. Vladimir Yutkin, Director of Urologic oncology at Hadassah, in collaboration with  Prof. Ofer Mandelboim, a leader in immunotherapy, and Prof. Gilad Bachrach, an expert in bacterio-oncology, both from Hebrew University researchers, provides for a unique approach and has demonstrated immense potential in pre-clinical studies on animal models. Hopec Pharma is now gearing up for Phase I trials in humans, focusing on Non-Muscle Invasive Bladder Cancer (NMIBC).

Noxon is developing a groundbreaking drug to combat Idiopathic Pulmonary Fibrosis (IPF), a devastating disease characterized by lung fibrosis and limited survival. Through collaboration between Prof. Neville Berkman, Director of the Hadassah Department of Pulmonary Medicine and researchers from the Hebrew University of Jerusalem - Prof. Sara Goldstein and Prof. Amram Samuni,  a novel drug called 3-cabamoyl-proxyl (3-CP) has been discovered that holds immense potential to offer a safe and effective approach in the battle against IPF.

OrSight  is developing a treatment for Age-related Macular Degeneration (AMD), one of the leading causes of blindness worldwide. The novel treatment offers a potentially higher effectiveness solution compared to existing treatments, and is aimed to significantly improve patient compliance, a main problem with the current standard of care. The company was co-founded by Prof. Itay Chowers, Chairman of the Hadassah Department of Ophthalmology, and Prof. Ofra Benny from the Hebrew University of Jerusalem. The company was established as part of NGT Healthcare Fund II in 2023.

EverlyBio, spun off in partnership with  VLX Ventures, is leveraging deep molecular data and utilizing computational biology to drive advancements in in vitro fertilization (IVF). The company aims to develop standardized diagnostics, improve implantation success rates, and identify novel biological interventions during the IVF process. This remarkable progress stems from a tri-lateral collaboration by Dr. Tal Imbar, Head of the Fertility Preservation Service at Hadassah IVF Unit, Prof. Yael Heifetz, Hebrew University, and Prof. Noam Shomron, Tel Aviv University.

GHF – Golden Heart Flower Ltd. was established to support people with glycogen storage diseases with limited treatment options. The company is developing a portfolio of oral medicines that target underlying disease pathogenesis. Based on the lead compound’s mechanism of action, larger commercial opportunities are being pursued. GHF was established by an entrepreneur who wanted to find a cure for his mother’s disease, and acquired the license from Or Kakhlon’s Laboratory of Experimental Neurology at Hadassah, in collaboration with Prof. Miguel Weil from Tel-Aviv University. Prof. Alexander Lossos opened the first clinical site at Hadassah Hospital.

EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy. The technology originates from collaboration between Dr. Sharon Merims, senior dermatologist and Head of the skin toxicity clinic at the Sharett Institute of Oncology at Hadassah Medical Center and Prof. Ofra Benny, an associate professor at the Institute for Drug Research in the School of Pharmacy at the Hebrew University.

Inspired by the virtues of breast milk and its unique health properties, EXOSOMM is developing an exciting step towards care and quality of life for patients suffering from inflammatory bowel diseases (IBD). The company is backed by Prof. Shimon Reif, Head of the Department of Pediatrics at Hadassah, Dr. Regina Golan-Gerstl, Director of the Hadassah Pediatric Laboratory, and Dr.Yaffa Elbaum-Shiff, Deputy Director of the Department of Nutrition at Tel Aviv Medical Center, and led by CEO Netta Granot. Exosomm harnesses the natural properties of milk-derived nano-molecules found naturally in mammalian milk by creating a portfolio of exosomes-based nutritional solutions. The company was established in partnership with the Galil-Ofek incubator.

In October 2022 Hadasit in partnership with VLX Ventures has spun off a new cell therapy company called Sakura Bio. The company arises from the proprietary technology invented by Prof. Amnon Peled, Head of the Hadassah Gene Therapy Institute, and shall focus on developing SAK (super activated killer T cells). This is an off the shelf, allogenic T-cell therapy produced via a simple, relatively shot manipulation of naïve PBMC, applicable to a variety of cancers and particularly effective in acute myeloid leukemia (AML).

Cell Cure Neurosciences Ltd., a subsidiary of BioTime, Inc., is a biotechnology company focused on developing cell therapies for retinal and neural degenerative diseases. Cell Cure technology is based on human embryonic stem cells (hESC), which, for the first time in the history of medicine, open the door to industrial-scale manufacture of any cell type in the human body. Cell Cure is using these powerful stem cells to manufacture a particular cell type in the retina called the Retinal Pigment Epithelial (RPE) cell.

Granalix Ltd. generates innovative formulations of natural compounds that increase their bioavailability and allow them to target organs of interest and, in particular, the brain. The company’s first product – GranaGard – is a submicron self-emulsion formulation of pomegranate seed oil (PSO). PSO contains high concentrations of Punicic Acid (PA), among the strongest natural antioxidants. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease which presents neurodegenerative features reminiscent of Alzheimer’s disease and to reduce disease burden in a mouse model of Multiple Sclerosis.

Cordio is a health tech company, developing  machine learning software that can be downloaded to a smartphone and help keeps cardiac patients out of the hospital. Using only the patient speech, sampled via mobile device, Cordio HearO™ can sense fluid accumulation related to CHF and alert prior to hospitalization. The HearO™ is the first easy to use, non-invasive, medical grade CHF monitoring device that patients actually want to use! Cordio was established in 2013 based on the invention of Prof. Chaim Lotan from Hadassah, and entered Incentive incubator in 2015. Raised so far about $25 million in capital from Peregrine Ventures, Ceros Financial Services and other investors.

Nobio develops, manufactures, and commercializes QASi, a novel, best-in-class antibacterial technology for medical and dental applications. Nobio has successfully developed and launched an antibacterial composite resin material called Infinix™, which incorporates the QASi particles. Infinix is a complete restorative system (including bonding agent and composites), and is the first FDA-cleared antimicrobial dental composite system with clinical claims of reducing demineralization, which is the critical part of the onset of the caries-formation process.

KAHR Medical Ltd. (“KAHR”) is an immuno-oncology drug development company whose mission is to develop novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. KAHR’s drug development pipeline is built around the Dual Signaling Proteins (DSP) technology which harnesses the power of the TNF Superfamily (regulators of the immune system) for treatment of disease. KAHR actively operates two drug-development programs, KAHR-101 and KAHR-102, representing proof-of-concept for its two proprietary platforms.

Enlivex was founded to advance the pioneering research of Professor Dror Mevorach, an expert in immune activity, macrophage activation, and the clearance of apoptotic (dying) cells. Based on the technology developed by Prof. Dror Mevorach in collaboration with Hebrew University  researchers the groundbreaking apoptotic cell-based platform, Allocetra™ came to life to treat various acute and chronic inflammatory diseases. Today, Allocetra™ stands as a fully off-the-shelf, frozen, and cost-effective therapeutic product, readily available for clinical use. It has been successfully administered to over 150 patients with favorable safety profile and no drug related severe adverse effects. 

Moebius Medical Ltd. is a clinical stage biotechnology company which is developing a novel and sustainable pain relief treatment for osteoarthritis. The company’s lead product for osteoarthritis of the knee, MM-II, leverages the physical properties of proprietary liposomes to lubricate the joint and reduce friction and wear, thus leading to joint pain reduction.

Novel groundbreaking non-invasive guided intubation device, that enables clear identification of the trachea, as well as fast, accurate and safe intubations even in the most difficult clinical scenarios in which visualization of the trachea is very limited. The product is ISO 13485 certified and received the CE Mark and the FDA market approval.

Immuron Ltd. is a publicly-listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally-stable therapeutic as a potential oral targeted therapy for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in their pathogenesis.

Dio Tree is developing first-in-class small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, a major driver in many types of cancer, specifically, ovarian cancer. The molecule was developed by: Prof. Bernard Lerer, Founder of Hadassah’s Biological Psychiatry Laboratory and Hadassah BrainLabs;Dr. Tzuri Lifschytz of the Biological Psychiatry Laboratory; and Prof. Govindasamy Mugesh from the National Institute of Science in India. Prof. Lerer joined forces with Prof. Osnat Ashur-Fabian, Director of the Laboratory for Applied Oncology Research at the Hematology Institute at Meir Hospital, who led the preclinical study. This unique collaboration led to the establishment of DioTree.

Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Founded by leading patient organizations and biotechnology industry veterans, Akashi is managed by a seasoned team of drug development experts. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a fatal, aggressive muscle-wasting disease to a chronic, manageable condition.

Insuline Medical is a publicly-listed Israeli medical device company (INSL.TA). They developed a device that enables patients on intensive insulin therapy to take control of their disease and reach treatment targets in a more effective way. Insuline Medical has been active in developing a new approach to insulin therapy care since 2007, and has developed two medical devices using similar technology. InsuPatch & InsuPad are both designed to improve the current meal-time insulin therapy.

Immunyx is a drug development company focused on modulating neutrophil function to treat disease. Numerous high burden illnesses such as COPD, cancer, and arthritis involve deregulated neutrophils which exacerbate, and sometimes cause, the underlying pathology. Using its platform technology to specifically manipulate neutrophils using a targeted nanoparticle, Immunyx will bring new therapies to several diseases where neutrophil treatment could advance a cure. Currently there are no FDA approved drugs targeting neutrophil activity in disease, providing Immunyx the potential to provide first in class therapies for a variety of diseases. Immunyx was established in collaboration with VLX incubator, based on the development of Prof. Zvi Friedlander, Director of the Department of Internal Medicine and Corona at Hadassah Ein Kerem, Prof. Zvika Granot and Dr. Seth Salpeter from the Hebrew University.

SwiftDuct  is a spinoff of the Biodesign program operated by Hadassah Medical Center and The Hebrew University of Jerusalem. Hadassah physicians Dr. Yeugeny Plotkin  and Dr. Abed Khalaileh are one of the inventors  of the primary technology.  SwiftDuct’s technology is designed to empower gastroenterologists to take the right path directly to the bile duct, safely, efficiently, and quickly while reducing the risks of side effects and radiation exposure to patients and medical teams. The SwiftDuct Navigation Kit, which includes the Swiftome™ and the SwiftGlide™ is designed to provide exceptional navigation capabilities for gastroenterologists to perform faster, easier and safer ERCP procedures. SwiftDuct is a portfolio company of MEDX Xelerator and located at MEDX’s North Branch in Sakhnin, Israel.

NeuroGenesis is a clinical stage cellular therapy company focusing on a proprietary subpopulation of bone marrow stem cells that are selected and enhanced to become remyelinating & regenerative biofactory cells. The platform NG CELL™️ technology is optimized to treat central nervous system diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

HighRAD provides an Intelligent Computer Assessment Support (iCAS )solution for a short and accurate assessment in the radiological follow-up of common pathologies for multiple organs and modalities.​ HighRAD’s products are designed around its novel Region of Difference (ROD ) generic platform and methodology for automatic, robust, and accurate lesion changes analysis in longitudinal volumetric scans, including CT and MRI scans. The ROD     technology was born from the collaboration of Prof. Leo Joskowicz, Head of the Computer-Assisted Surgery and Medical Image Processing Laboratory at the Hebrew University and Prof. Jacob Sosna, MD, Head of CT, and Director of the 3D Imaging Laboratory at Hadassah Medical Center.

CardioVia provides the physicians with a minimally invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and arrhythmias without using a needle. ​By using cutting edge technologies with the simplest ideas CardioVia will facilitate performance of surgeries on the outer surface of the heart like never seen before.